Author(s):
Uli Mas’uliyah Indarwati, Puspa Wardhani, Muhamad Robi’ul Fuadi, Soebagijo Adi Soelistijo
Email(s):
puspa-w-2@fk.unair.ac.id
DOI:
10.52711/0974-360X.2024.00197 
Address:
Uli Mas’uliyah Indarwati1,7, Puspa Wardhani2,5,6*, Muhamad Robi’ul Fuadi2,3, Soebagijo Adi Soelistijo4
1Master Program of Basic Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Teaching Hospital, Surabaya, Indonesia.
3Universitas Airlangga Hospital, Surabaya, Indonesia.
4Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Teaching Hospital, Surabaya, Indonesia.
5Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.
6Postgraduate School of Universitas Airlangga, Surabaya, Indonesia.
7Department of Medical Laboratory Technology, Faculty of Health Sciences, Universitas Muhammadiyah Purwokerto, Indonesia.
*Corresponding Author
Published In:
Volume - 17,
Issue - 3,
Year - 2024
ABSTRACT:
Background: Growth Differentiation Factor 15 (GDF-15) has been identified as a biomarker of cellular stress conditions and has demonstrated functional implications in kidney disease, metabolic disorders, and diabetes. However, the relationship between GDF-15 and the coexistence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) remains unclear. This study aims to investigate the association between GDF-15 levels and the presence of CKD in patients with T2DM, then analyze the cut off value. Method: A cross-sectional study was conducted, enrolling a total of 60 patients. T2DM patients were categorized into two groups based on the presence or absence of CKD. Serum GDF-15 levels were quantified using an enzyme-linked immunosorbent assay (ELISA) kit. Results: The study population (n=60) predominantly consisted of male individuals with an average age of 53 years. The receiver operating characteristic (ROC) curve analysis yielded an area under the curve (AUC) of 0.846 (95% CI = 0.748 – 0.945) with a statistically significant p-value of < 0.001. The optimal cut-off value for serum GDF-15 to detect the presence of CKD was determined as 362.80 pg/mL, with corresponding sensitivity and specificity values of 77% and 79%, respectively. Furthermore, a significant association between GDF-15 levels and both T2DM without CKD and T2DM with CKD was observed (p < 0.001). Conclusion: There is a significant association observed between serum GDF-15 levels in patients with type 2 diabetes mellitus (DM) and the presence of CKD. The cut of value GDF-15 to detect the presence of CKD was determined as 362.80 pg/mL with sensitivity and specificity values of 77% and 79%, this is can be considered as a potential biomarker for the detection of CKD in individuals with T2DM.
Cite this article:
Uli Mas’uliyah Indarwati, Puspa Wardhani, Muhamad Robi’ul Fuadi, Soebagijo Adi Soelistijo. Serum Levels of Growth Differentiation Factor 15 as a Biomarker for Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2024; 17(3):1262-6. doi: 10.52711/0974-360X.2024.00197
Cite(Electronic):
Uli Mas’uliyah Indarwati, Puspa Wardhani, Muhamad Robi’ul Fuadi, Soebagijo Adi Soelistijo. Serum Levels of Growth Differentiation Factor 15 as a Biomarker for Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2024; 17(3):1262-6. doi: 10.52711/0974-360X.2024.00197 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-3-48
REFERENCES:
1. Bao X, Borné Y, Muhammad IF, et al. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer–Cardiovascular Cohort. Diabetologia. 2019; 62(1): 78-86. doi:10.1007/s00125-018-4751-7
2. Emmerson PJ, Duffin KL, Chintharlapalli S, Wu X. GDF15 and Growth Control. Front Physiol. 2018; 9: 1-7. doi:10.3389/fphys.2018.01712
3. Rochette L, Zeller M, Cottin Y, Vergely C. Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets. Trends Endocrinol Metab. 2020;31(12):939-951. doi:10.1016/j.tem.2020.10.004
4. Frimodt-Møller M, Von Scholten BJ, Reinhard H, et al. Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study. PLoS One. 2018; 13(4): 1-13. doi:10.1371/journal.pone.0196634
5. Chung JO, Chung MY, Park SY, Cho DH, Chung DJ. Relationship between plasma growth differentiation factor-15 level and estimated glomerular filtration rate in type 2 diabetes patients with and without albuminuria. J Diabetes Complications. 2021;35(4):107849. doi:10.1016/j.jdiacomp.2021.107849
6. Carlsson AC, Nowak C, Lind L, et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020; 125(1): 37-43. doi:10.1080/03009734.2019.1696430
7. Ruszała M, Niebrzydowska M, Pilszyk A, Kimber-Trojnar Ż, Trojnar M, Leszczyńska-Gorzelak B. Novel biomolecules in the pathogenesis of gestational diabetes mellitus. Int J Mol Sci. 2021; 22(21). doi:10.3390/ijms222111578
8. Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients. Int Urol Nephrol. 2016; 48(6): 839-844. doi:10.1007/s11255-016-1278-z
9. Abdurachman A, Rubiyanto A, Suhariningsih S, Hendromartono H, Gunawan A. The optimal dose of the Low-level laser therapy in the treatment of type 1 Diabetes Mellitus. Bali Med J. 2018; 7(1): 7-11. DOI: https://doi.org/10.15562/bmj.v7i1.527
10. Trisnadewi NW, Adiputra IMS, Oktaviani NPW, Suapriyanti PA, Intan Saraswati NLG. Correlation between stress level and family support towards fasting and postprandial glucose level in type 2 diabetes mellitus. Bali Med J. 2020; 9(3): 811-5. DOI: https://doi.org/10.15562/bmj.v9i3.2006
11. Al-Rubaye AAH. The Correlation between Type 2 Diabetes Mellitus and Hypertension in Iraqi Patients. J. Med. Chem. Sci., 2023; 6(4): 778-788. https://doi.org/10.26655/JMCHEMSCI.2023.4.9
12. Al-Obaidi MJ, Al-Ghurabi BH. Potential Role of NLRP3 Inflammasome Activation in the Pathogenesis of Periodontitis Patients with Type 2 Diabetes Mellitus. J. Med. Chem. Sci., 2023; 6(3): 522-531. https://doi.org/10.26655/JMCHEMSCI.2023.3.9
13. IDF. 537 Million People Worldwide Have Diabetes. 10th editi.; 2021. https://diabetesatlas.org
14. Dhenok Palupi F, Wasita B, Patriadi Nuhriawangsa AM. The potency of Centella asiatica in protecting organs of rats with type 2 diabetes mellitus. Bali Med J. 2019; 8(1): 316-21. DOI: https://doi.org/10.15562/bmj.v8i1.1229
15. Dwipayanti NMA, Nariata IW, Aryana IGPS. Diabetes mellitus control among elderly patients at geriatric polyclinic of Karangasem District Hospital, Bali, Indonesia: a preliminary study. Bali Med J. 2020; 9(1): 279-85. DOI: https://doi.org/10.15562/bmj.v9i1.1664
16. Kashtl GJ, Abed BA, Farhan LO, Salman IN, Dawood AS. A Comparative Study to Determine LDH Enzyme Levels in Serum Samples of Women with Breast Cancer and Women with Breast Cancer and Type 2 Diabetes Mellitus. J. Med. Chem. Sci., 2023; 6(4): 883-890. https://doi.org/10.26655/JMCHEMSCI.2023.4.20
17. Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int. 2021;2021. doi:10.1155/2021/1497449
18. Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New potential biomarkers for chronic kidney disease management — A review of the literature. Int J Mol Sci. 2021; 22(1): 1-37. doi:10.3390/ijms22010043
19. ADA. Standards of medical care in diabetes—2020 abridged for primary care providers. Clin Diabetes. 2020; 38(1): 10-38. doi:10.2337/cd20-as01
20. Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes, Obes Metab. 2020; 22(S1): 3-15. doi:10.1111/dom.14007
21. Handoko E, Dyah I, Utomo SP, Apriannisa A. Correlation between Otic Capsule Density and Serum 25(OH)D with hearing threshold in chronic kidney disease. Bali Med J. 2017; 6(2): 436-9. DOI: https://doi.org/10.15562/bmj.v6i2.560
22. Rusyati LMM, Kandarin Y, Priliawati NNT. High serum interleukin-2 levels are associated with pruritus in chronic kidney disease undergoing regular hemodialysis. Bali Med J. 2020; 9(3): 672-5. DOI: https://doi.org/10.15562/bmj.v9i3.2018
23. Mohamed HS, Alhabibi AM, Donia AAE, Elsawy GM, Ibrahim NR, Mohamed MA. Expression of MicroRNA-155-5p in Chronic Kidney Disease As a Potential Marker of Cardiovascular Complications. J. Med. Chem. Sci., 2023; 6(8): 1737-1745. https://doi.org/10.26655/JMCHEMSCI.2023.8.3
24. Wischhusen J, Melero I, Fridman WH. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020; 11. doi:10.3389/fimmu.2020.00951
25. Hussain S, Habib A, Hussain MS, Najmi AK. Potential biomarkers for early detection of diabetic kidney disease. Diabetes Res Clin Pract. 2020; 161: 108082. doi:10.1016/j.diabres.2020.108082
26. Shin MY, Kim JM, Kang YE, et al. Association between growth differentiation factor 15 (GDF15) and cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus. J Korean Med Sci. 2016; 31(9): 1413-1418. doi:10.3346/jkms.2016.31.9.1413
27. Kim JS, Kim S, Won CW, Jeong KH. Association between plasma levels of growth differentiation factor-15 and renal function in the elderly: Korean frailty and aging cohort study. Kidney Blood Press Res. 2019; 44(3): 405-414. doi:10.1159/000498959
28. Kim Y, Noren Hooten N, Evans MK. CRP stimulates GDF15 expression in endothelial cells through p53. Mediators Inflamm. 2018; 2018. doi:10.1155/2018/8278039
29. Conte M, Martucci M, Mosconi G, et al. GDF15 Plasma Level Is Inversely Associated With Level of Physical Activity and Correlates With Markers of Inflammation and Muscle Weakness. Front Immunol. 2020; 11: 1-10. doi:10.3389/fimmu.2020.00915
30. Wada H, Suzuki M, Matsuda M, et al. Impact of smoking status on growth differentiation factor 15 and mortality in patients with suspected or known coronary artery disease: The anox study. J Am Heart Assoc. 2020; 9(22): 1-12. doi:10.1161/JAHA.120.018217
31. Buendgens L, Yagmur E, Bruensing J, et al. Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsis. Dis Markers. 2017; 2017. doi:10.1155/2017/5271203
32. Santoso B, Rahmawati NY, Sa’adi A, et al. Elevated peritoneal soluble endoglin and GDF-15 in infertile women with severe endometriosis and pelvic adhesion. J Reprod Immunol. 2021; 146: 103343. doi:10.1016/j.jri.2021.103343
33. Xiao QA, He Q, Zeng J, Xia X. GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease. Biomed Pharmacother. 2022;146(October 2021):112582. doi:10.1016/j.biopha.2021.112582
34. Uwaezuoke SN. The role of novel biomarkers in predicting diabetic nephropathy: A review. Int J Nephrol Renovasc Dis. 2017; 10: 221-231. doi:10.2147/IJNRD.S143186
35. Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018; 117(8): 662-675. doi:10.1016/j.jfma.2018.02.007
36. Niu Y, Zhang W, Shi J, et al. The Relationship Between Circulating Growth Differentiation Factor 15 Levels and Diabetic Retinopathy in Patients With Type 2 Diabetes. Front Endocrinol (Lausanne). 2021; 12: 1-8. doi:10.3389/fendo.2021.627395
37. Babalghith AO, Al-kuraishy HM, Al-Gareeb AI, et al. The Potential Role of Growth Differentiation Factor 15 in COVID-19: A Corollary Subjective Effect or Not? Diagnostics. 2022; 12(9). doi:10.3390/diagnostics12092051